Promising data for DNA ‘reverse’ vaccine against Type 1 diabetes

A vaccine designed to combat type-1 diabetes mellitus (T1DM) has delivered promising results in a phase II clinical trial. Researchers at Stanford University School of Medicine trialled the DNA ‘reverse' vaccine in 80 patients with T1DM and taking insulin, and found that in the vaccine group, levels of C-peptide (a proxy of insulin production) were maintained or even occasionally increased …